Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 621 - 632
Published: Jan. 1, 2024
Language: Английский
Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12
Published: Jan. 22, 2025
Parkinson’s disease is a progressive neurodegenerative that destroys substantia nigra dopaminergic neurons, causing tremors, bradykinesia, rigidity, and postural instability. Current treatment approaches primarily focus on symptom management, employing pharmacological, non-pharmacological, surgical methods. However, these treatments often result in fluctuating symptoms, side effects, progression. Here, the authors have reviewed emerging field of nanomedicine as promising path for treatment, emphasizing its potential to overcome limitations traditional therapies. Nanomedicine utilizes nanoparticles targeted drug delivery, leveraging their small size high surface area volume ratio cross blood-brain barrier deliver therapeutic agents directly affected brain regions. Various nanoparticles, including lipid-based, polymeric, metallic, carbon-based, shown treatment. Additionally, nanocarrier systems like liposomes, nanogels, dendrimers, solid lipid offer controlled sustained release agents, enhancing bioavailability reducing effects. This review provides insights into pathophysiology disease, highlighting mechanisms neurodegeneration, role alpha-synuclein, disruption pathways. It further discusses application gene therapy conjunction with interventions.
Language: Английский
Citations
2
Neurobiology of Disease, Journal Year: 2023, Volume and Issue: 187, P. 106314 - 106314
Published: Oct. 1, 2023
Poly (ADP-ribose) polymerase-1 (PARP-1) is the most extensively studied member of PARP superfamily, with its primary function being facilitation DNA damage repair processes. Parthanatos a type regulated cell death cascade initiated by PARP-1 hyperactivation, which involves multiple subroutines, including accumulation ADP-ribose polymers (PAR), binding PAR and apoptosis-inducing factor (AIF), release AIF from mitochondria, translocation AIF/macrophage migration inhibitory (MIF) complex, massive MIF-mediated fragmentation. Over past few decades, role in central nervous system health disease has received increasing attention. In this review, we discuss biological functions neural proliferation differentiation, memory formation, brain ageing, epigenetic regulation. We then elaborate on involvement PARP-1-dependant parthanatos various neuropathological processes, such as oxidative stress, neuroinflammation, mitochondrial dysfunction, excitotoxicity, autophagy damage, endoplasmic reticulum (ER) stress. Additional highlight contains PARP-1's implications initiation, progression, therapeutic opportunities for different neurological illnesses, neurodegenerative diseases, stroke, autism spectrum disorder (ASD), sclerosis (MS), epilepsy, neuropathic pain (NP). Finally, emerging insights into repurposing inhibitors management diseases are provided. This review aims to summarize exciting advancements critical disorders, may open new avenues options targeting or parthanatos.
Language: Английский
Citations
28
Molecular Neurobiology, Journal Year: 2024, Volume and Issue: unknown
Published: April 4, 2024
Language: Английский
Citations
5
Biochemical Society Transactions, Journal Year: 2024, Volume and Issue: 52(3), P. 1275 - 1291
Published: May 30, 2024
Parkinsonism is the primary type of movement disorder in adults, encompassing a set clinical symptoms, including rigidity, tremors, dystonia, bradykinesia, and postural instability. These symptoms are primarily caused by deficiency dopamine (DA), an essential neurotransmitter brain. Currently, DA precursor levodopa (synthetic L-DOPA) standard medication to treat deficiency, but it only addresses rather than provides cure. In this review, we provide overview disorders associated with dysregulation particularly Parkinson's disease rare inherited leading predominantly dystonia and/or parkinsonism, even childhood. Although relatively effective for management motor dysfunctions, less severe forms parkinsonism also side effects loss efficacy over time. We present ongoing efforts reinforce effect develop innovative therapies that target underlying pathogenic mechanisms affecting synthesis transport, increasing neurotransmission through disease-modifying approaches, such as cell-based therapies, nucleic acid- protein-based biologics, small molecules.
Language: Английский
Citations
5
ACS Biomaterials Science & Engineering, Journal Year: 2024, Volume and Issue: 10(8), P. 5039 - 5056
Published: July 9, 2024
Parkinson's is a progressive neurodegenerative disease of the nervous system. It has no cure, but its symptoms can be managed by supplying dopamine artificially to brain.This work aims engineer tricompartmental polymeric microcarriers electrohydrodynamic cojetting technique encapsulate three PD (Parkinson's disease) drugs incorporated with high encapsulation efficiency (∼100%) in single carrier at fixed drug ratio 4:1:8 (Levodopa (LD): Carbidopa(CD): Entacapone (ENT)). Upon oral administration, needs maintained during subsequent release from microparticles enhance bioavailability primary LD. This presents notable challenge, as vary their aqueous solubility (LD > CD ENT). The equilibrium therapeutic was achieved using combination FDA-approved polymers (PLA, PLGA, PCL, and PEG) disc shape particles.
Language: Английский
Citations
5
Frontiers in Bioengineering and Biotechnology, Journal Year: 2024, Volume and Issue: 12
Published: Aug. 8, 2024
Introduction Parkinson’s disease (PD) presents a significant challenge in medical science, as current treatments are limited to symptom management and often carry side effects. Our study introduces an innovative approach evaluate the effects of gdnf overexpression mediated by CRISPRa vitro model disease. The expression can have neuroprotective effects, being related modulation neuroinflammation pathways associated with cell survival, differentiation, growth. Methods We developed targeted delivery system using magnetite nanostructured vehicle for efficient transport genetic material. This has resulted substantial increase, up 200-fold) In mixed primary culture astrocytes, neurons, microglia. Results Discussion exhibits endosomal escape more than 56%, crucial effective activation material within cells. increased correlates notable reduction MAO-B complex activity, reaching basal values 14.8 μU/μg protein, reactive oxygen species. Additionally, there is 34.6% increase viability treated neurotoxin MPTP. shows that increasing remediate some cellular symptoms novel system.
Language: Английский
Citations
5
NeuroSci, Journal Year: 2025, Volume and Issue: 6(1), P. 6 - 6
Published: Jan. 15, 2025
Background: Parkinson’s disease (PD) is a progressive neurodegenerative condition characterized by the degradation of dopaminergic pathways in brain. As population United States continues to age, it essential understand trends mortality related PD. This analysis PD’s characterizes temporal shifts, examines demographic and regional differences, provides machine-learning predictions. Methods: PD-related deaths were gathered from CDC WONDER. Age-adjusted rates (AAMR) collected, analyzed based on gender, race, region, place death. Annual percent change average annual calculated using Joinpoint Regression program. Forecasts obtained optimal Autoregressive Integrated Moving Average (ARIMA) model. Results: Overall rate due increased 1999 2022. Male White Southern older ages associated with higher compared other groups. Deaths at home decreased hospice during study period. Conclusions: highlights increasing PD AAMR how may become even more prevalent time, emphasizing value knowledge surrounding its better prepare health systems individual families for burden
Language: Английский
Citations
0
Strength and conditioning journal, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 17, 2025
ABSTRACT Parkinson disease (PD) is a progressive and chronic neurodegenerative disorder that compromises both motor nonmotor functions, ultimately leading to decline in functional capacity quality of life. Although the etiology PD multifaceted, exercise has shown promising effects managing symptoms enhancing patient well-being. aerobic resistance demonstrate benefits within this specific population, exact application these modalities varies often differs depending on progression individual. individuals diagnosed with are encouraged exercise, there still lack information pertaining how successfully structure physical activity into their daily routine. There also distinct barriers motivators impacting decision engage regular exercise. This manuscript offers practical recommendations personalized guidelines for professionals, empowering them optimize management through targeted interventions. In addition, it current promoting among patients PD, specifically enhance outcomes.
Language: Английский
Citations
0
Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)
Published: Feb. 19, 2025
Language: Английский
Citations
0
Cells, Journal Year: 2025, Volume and Issue: 14(5), P. 338 - 338
Published: Feb. 26, 2025
Parkinson's disease (PD) represents a growing challenge to global health, as it involves millions of people. The high grade disability is due the loss dopaminergic neuron activity, and levodopa gold-standard therapy used restore dopamine in dopamine-denervated regions. Another therapeutic approach use A2A adenosine receptor antagonists and, among them, istradefylline only one currently approved for association with levodopa. In this work, we synthesized represented by 9-ethyl-2,8-disubstituted adenine derivatives, which were tested at human receptors binding functional assays. These compounds showed receptor-binding affinities low nanomolar range 1, 4, 5 exhibited good potency Hence, they evaluated vivo rat models PD, where demonstrated revert haloperidol-induced catalepsy potentiate levodopa-induced contralateral rotations 6-hydroxydopamine-lesioned rats. most potent derivative, was then tacrine model, reduced tremulous jaw movements, therefore demonstrating an action on parkinsonian tremor. data revealed 8-ethoxy-2-phenethoxy-9-ethyladenine (4) antagonist endowed antiparkinsonian effects candidate treat disease.
Language: Английский
Citations
0